news
Novavax presents positive data from Phase I COVID-19 vaccine trial
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
List view / Grid view
R&D
Filter the results
Whitepapers/App Notes/Posters
Data sheet: Viral RNA extraction from saliva and swab samples
RNAdvance Viral Kits. High-quality RNA extraction from saliva or swab transport media. Automation ready. LoD demonstrated at 1 copy/μL.
news
Commonly used treatments for chronic pain do not work, says NICE
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
news
Interleukin-6 inhibitors improve outcomes for COVID-19 patients in study
Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.
Whitepapers/App Notes/Posters
Application note: Streamlined Synthetic Biology with Acoustic Liquid Handling
Reduce input sample to femtomolar levels. Miniaturise gene assembly reactions up to 100-fold. Streamline NGS verification of assembly.
webinar
Delivering value: how LIMS can enable data integrity in pharma manufacturing
4 August 2020 | By Thermo Fisher Scientific
Find out more about industry issues, solutions, trends and how LIMS can enable laboratories to accelerate science and drive productivity, while ensuring regulatory compliance in our upcoming webinar.
Whitepapers/App Notes/Posters
Application note: Automated ELISA solutions – workflow intelligence guide
ELISA protocols involve an exhausting number of dispensing, washing and incubating steps. Get your guide to automated ELISA workflow intelligence here.
news
UK to roll out COVID-19 diagnostic that provides results in under two hours
An initial 450,000 of Oxford Nanopore's LamPORE test will be used by the UK government as COVID-19 diagnostics, which yield results in under two hours.
news
Moderna initiates Phase III trial of COVID-19 vaccine candidate
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
Whitepapers/App Notes/Posters
Application note: Miniaturised multi-piece DNA assembly
The Echo Liquid Handler has demonstrated the ability to generate DNA constructs using various assembly chemistries with a miniaturised protocol.
news
US invests over $240 million into seven new COVID-19 diagnostic tests
The National Institutes of Health in the US has awarded contracts to seven biomedical companies to develop and manufacture COVID-19 diagnostics.
news
UKRI announces six research initiatives into COVID-19 and ethnicity
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
webinar
The analytical reality of recombinant endotoxin technologies
29 July 2020 | By Charles River
Endotoxin tests using recombinant technology have been receiving a lot of attention lately. After a careful analysis of our 2019 study on the alternative methods, we conducted a second, larger study with hundreds of global water samples evaluating rFC products, including our own in development. Sign up for our webinar…
news
PQE Group creates an internal research Task Force to fight fake news in relation to COVID-19
The CEO of PQE Group has formed a task force of employees in the corporate community to research and dispel fake news regarding COVID-19.
news
Potential COVID-19 treatment LAM-002A to enter Phase II clinical trial
Yale University and AI Therapeutics will collaborate on a Phase II trial to study LAM-002A as a COVID-19 treatment for newly diagnosed patients.